Ryan Flannery
Family Medicine · Washington, IANPI 1114981396
Payments from drug & device makers
Across 88 payments — averaging $11.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$313
- Pfizer$176
- Amgen$157
- AstraZeneca$81
- GSK$52
- Novo Nordisk$29
- plus $215 from 12 others
What the payments were for
- Food & beverage$1,022100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 23 | $313 |
| Pfizer | 25 | $176 |
| Amgen | 11 | $157 |
| AstraZeneca | 6 | $81 |
| GSK | 4 | $52 |
| Novo Nordisk | 2 | $29 |
| AbbVie | 2 | $28 |
| Ironshore Pharmaceuticals Inc. | 2 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $24 |
| Teva Pharmaceuticals USA, Inc. | 2 | $23 |
| Boehringer Ingelheim | 2 | $23 |
| Merck | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| Lilly USA, LLC | 1 | $12 |
| Novartis | 1 | $11 |
| Johnson & Johnson | 1 | $11 |
How this compares
$1,022 in reported general payments places this provider in the 80th percentile of 1,357 family medicine providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 71 | $57,132 |
| OzempicSemaglutide | 44 | $50,463 |
| JardianceEmpagliflozin | 59 | $43,565 |
| XareltoRivaroxaban | 26 | $16,273 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $15,941 |
| JanuviaSitagliptin Phosphate | 18 | $13,748 |
| EntrestoSacubitril/Valsartan | 15 | $13,499 |
| TrulicityDulaglutide | 11 | $12,938 |
| MyrbetriqMirabegron | 19 | $6,624 |
| Spiriva RespimatTiotropium Bromide | 12 | $6,148 |
| Atrovent HfaIpratropium Bromide | 12 | $5,504 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $4,799 |
| Novolog FlexpenInsulin Aspart | 11 | $4,544 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $4,395 |
| Dexlansoprazole DrDexlansoprazole | 16 | $3,984 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Dilantin | $176 | $59,47283 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $23 | $54,51282 claims |
| Novo NordiskOzempic | $29 | $50,46344 claims |
| Johnson & JohnsonXarelto | $11 | $16,27326 claims |
| GSKAnoro Ellipta | $52 | $15,94132 claims |
| MerckJanuvia | $16 | $13,74818 claims |
| NovartisEntresto | $11 | $13,49915 claims |
| Lilly USA, LLCTrulicity | $12 | $12,93811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,357 family medicine providers in Iowa.
Other family medicine in Washington
- Nicholas GoetschWaterloo$4.1M
- James PoockWaterloo$1.5M
- Jennifer KayCouncil Bluffs$613K
- Nicholas BechtoldSioux City$584K
- Kirk PetersonHuxley$576K
- Stephen HarrisonClinton$249K
- Sharon SteenBelle Plaine$241K
- Carlos Alarcon SchroderJohnston$237K
- Thomas RossDes Moines$170K
- Yogesh ShahDes Moines$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.